EU/3/17/1877

About

On 22 May 2017, orphan designation (EU/3/17/1877) was granted by the European Commission to GB Pharma Srl, Italy, for tamoxifen citrate for the treatment of cystic fibrosis.

Key facts

Active substance
Tamoxifen citrate
Disease / condition
Treatment of cystic fibrosis
Date of first decision
22/05/2017
Outcome
Positive
EU designation number
EU/3/17/1877

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

GB Pharma Srl
Via Ferreri, 11
27100 Pavia
Italy
Tel. +39 382 530 059
E-mail: info@gbpharma.it

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating